Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2018

Commission File Number: 001-38475

 

 

ASLAN PHARMACEUTICALS LIMITED

(REG. NO. 289175)

(Exact name of Registrant as specified in its charter)

CAYMAN ISLANDS

(Jurisdiction of incorporation or organisation)

83 CLEMENCEAU AVENUE

#12-03 UE SQUARE

SINGAPORE 239920

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

Form 40-F:    ☒  Form 20-F    ☐  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      ASLAN PHARMACEUTICALS LIMITED
Date:   10 December, 2018   By:  

/s/ Kiran Kumar Asarpota

    Name:  

Kiran Kumar Asarpota

    Title:  

VP Finance


ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In U.S. Dollars)

(Unaudited)

 

 

     June 30, 2018     December 31, 2017  
     Amount     %     Amount     %  

ASSETS

        

CURRENT ASSETS

        

Cash and cash equivalents

   $ 44,952,396       65     $ 50,573,211       99  

Prepayments

     198,043       —         71,946       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Total current assets

     45,150,439       65       50,645,157       99  
  

 

 

   

 

 

   

 

 

   

 

 

 

NON-CURRENT ASSETS

        

Property, plant and equipment

     369,906       1       443,566       1  

Intangible assets

     23,083,850       34       84,052       —    

Refundable deposits

     191,739       —         160,947       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Total non-current assets

     23,645,495       35       688,565       1  
  

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL

   $ 68,795,934       100     $ 51,333,722       100  
  

 

 

   

 

 

   

 

 

   

 

 

 

LIABILITIES AND EQUITY

        

CURRENT LIABILITIES

        

Trade payables

   $ 3,354,095       5     $ 3,898,291       8  

Other payables

     2,388,089       3       2,080,544       4  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total current liabilities

     5,742,184       8       5,978,835       12  
  

 

 

   

 

 

   

 

 

   

 

 

 

NON-CURRENT LIABILITIES

        

Long-term borrowings

     9,715,329       14       9,679,451       19  

Other non-current liabilities

     486,000       1       162,000       —    
  

 

 

   

 

 

   

 

 

   

 

 

 

Total non-current liabilities

     10,201,329       15       9,841,451       19  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total liabilities

     15,943,513       23       15,820,286       31  
  

 

 

   

 

 

   

 

 

   

 

 

 

EQUITY

        

Ordinary shares

     51,587,993       75       41,514,016       81  

Capital surplus

     111,334,877       162       84,282,681       164  

Accumulated deficits

     (110,070,449     (160     (90,283,261     (176
  

 

 

   

 

 

   

 

 

   

 

 

 

Total equity

     52,852,421       77       35,513,436       69  
  

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL

   $ 68,795,934       100     $ 51,333,722       100  
  

 

 

   

 

 

   

 

 

   

 

 

 

 

1


ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In U.S. Dollars)

(Unaudited)

 

 

     For the Six Months Ended
June 30
 
     2018     2017  
     Amount     Amount  

OPERATING EXPENSES

    

General and administrative

   $ (5,871,931   $ (3,825,459

Research and development

     (13,945,341     (13,000,134
  

 

 

   

 

 

 

Total operating expenses

     (19,817,272     (16,825,593
  

 

 

   

 

 

 

LOSS FROM OPERATIONS

     (19,817,272     (16,825,593
  

 

 

   

 

 

 

NON-OPERATING INCOME AND EXPENSES

    

Other gains and losses

     264,287       (362,654

Finance costs

     (224,461     (204,756
  

 

 

   

 

 

 

Total non-operating income and expenses

     39,826       (567,410
  

 

 

   

 

 

 

LOSS BEFORE INCOME TAX

     (19,777,446     (17,393,003

INCOME TAX EXPENSE

     (9,742     —    
  

 

 

   

 

 

 

NET LOSS FOR THE PERIOD

     (19,787,188     (17,393,003
  

 

 

   

 

 

 

TOTAL COMPREHENSIVE LOSS FOR THE PERIOD

   $ (19,787,188   $ (17,393,003
  

 

 

   

 

 

 

LOSS PER SHARE

    

Basic

   $ (0.14   $ (0.15
  

 

 

   

 

 

 

 

2